These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 19213342)
1. [Efficacy of electroacupuncture in treating 93 patients with benign prostatic hyperplasia]. Yang T; Zhang XQ; Feng YW Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Nov; 28(11):998-1000. PubMed ID: 19213342 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study. Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810 [TBL] [Abstract][Full Text] [Related]
3. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818 [TBL] [Abstract][Full Text] [Related]
4. Electroacupuncture for moderate and severe benign prostatic hyperplasia: a randomized controlled trial. Wang Y; Liu B; Yu J; Wu J; Wang J; Liu Z PLoS One; 2013; 8(4):e59449. PubMed ID: 23593139 [TBL] [Abstract][Full Text] [Related]
5. Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases - a medium term, prospective, randomized comparison. Geavlete B; Stanescu F; Iacoboaie C; Geavlete P BJU Int; 2013 May; 111(5):793-803. PubMed ID: 23469933 [TBL] [Abstract][Full Text] [Related]
6. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms. Jhang JF; Jiang YH; Kuo HC Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211 [TBL] [Abstract][Full Text] [Related]
7. [Fushile: a safe and effective therapeutic for benign prostatic hyperplasia]. Shang XJ; Liu ZY; Liu ZF; Sun YH; Huang YF Zhonghua Nan Ke Xue; 2008 Mar; 14(3):227-30. PubMed ID: 18488335 [TBL] [Abstract][Full Text] [Related]
8. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes. Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305 [TBL] [Abstract][Full Text] [Related]
10. Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders. Samli MM; Dincel C Urol Int; 2004; 73(2):125-9. PubMed ID: 15331896 [TBL] [Abstract][Full Text] [Related]
11. [Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder]. Wang YY; Shi GW; He JY; Zhang YB Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1099-102. PubMed ID: 24432622 [TBL] [Abstract][Full Text] [Related]
12. Effect of Depth of Electroacupuncture on the IPSS of Patients with Benign Prostatic Hyperplasia. Yuan H; Wei N; Li Y; Yu L; Zhang Y; Ong WL; Bai N; Wang M; Fu Y; Liu Y Evid Based Complement Alternat Med; 2019; 2019():1439141. PubMed ID: 31915442 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of electroacupuncture and its cotreatment with electronic moxibustion in the treatment of patients with moderate benign prostatic hyperplasia using alpha blocker: Study protocol for an assessor-blinded, randomized controlled clinical trial. Kim HB; Kim YI; Jeon JH; Kim E; Kim JY; Kwon O; Choi YE; Yang C; Han CH Medicine (Baltimore); 2020 Apr; 99(15):e19678. PubMed ID: 32282720 [TBL] [Abstract][Full Text] [Related]
14. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan. Tsai YS; Lan SK; Ou JH; Tzai TS Clin Ther; 2007 Apr; 29(4):670-82. PubMed ID: 17617290 [TBL] [Abstract][Full Text] [Related]
15. [Electroacupuncture at Zhongji (CV 3) for treatment of benign hyperplasia of prostate: a multi-central randomized controlled study]. Liu QG; Wang CY; Jiao S; Tang LX; Peng MH; Tian LF; Ding WX; Zhao X; Lu SK; Fu YJ; Tan WL; Qin Y Zhongguo Zhen Jiu; 2008 Aug; 28(8):555-9. PubMed ID: 18767576 [TBL] [Abstract][Full Text] [Related]
16. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. Na YJ; Guo YL; Gu FL J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165 [TBL] [Abstract][Full Text] [Related]
17. The short-term effects of terazosin in Japanese men with benign prostatic hyperplasia. Horiuchi K; Tsuboi N; Suzuki Y; Yoshida K; Akimoto M J Nippon Med Sch; 2001 Apr; 68(2):181-5. PubMed ID: 11301364 [TBL] [Abstract][Full Text] [Related]
18. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group]. Fourcade RO Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142 [TBL] [Abstract][Full Text] [Related]
19. [Clinical observation on ziyin tongbi decoction in treating benign prostatic hyperplasia]. Guo J; Song CS; Han Q Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Dec; 28(12):1082-5. PubMed ID: 19317162 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of intraprostatic temperature-controlled microwave thermotherapy in patients with benign prostatic hyperplasia: results of a prospective, open-label, single-center study with 1-year follow-up. Gravas S; Laguna MP; de la Rosette JJ J Endourol; 2003 Aug; 17(6):425-30. PubMed ID: 12965071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]